Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Pharmaceuticals & Biotechnology | Small Cap
Health Score : 6.61Medico Remedies Ltd demonstrates a mixed financial performance. The company shows strong solvency, growth, and profitability, underpinned by decreasing debt levels and impressive growth in revenue, operating profit, and earnings per share. High returns on capital employed, equity, and assets further highlight its profitability. However, liquidity is a significant concern, with very low current, quick, and cash ratios indicating potential difficulties in meeting short-term obligations. Efficiency is also a notable weakness, with low turnover ratios suggesting challenges in asset utilization. While the company's coverage ratios are reasonable, the lack of dividend coverage is a point to consider. The company's valuation metrics are also weak. Overall, the company exhibits good long-term financial health but needs to address its short-term liquidity and operational efficiency.
Health Score : 6.61Medico Remedies Ltd demonstrates a mixed financial performance. The company shows strong solvency, growth, and profitability, underpinned by decreasing debt levels and impressive growth in revenue, operating profit, and earnings per share. High returns on capital employed, equity, and assets further highlight its profitability. However, liquidity is a significant concern, with very low current, quick, and cash ratios indicating potential difficulties in meeting short-term obligations. Efficiency is also a notable weakness, with low turnover ratios suggesting challenges in asset utilization. While the company's coverage ratios are reasonable, the lack of dividend coverage is a point to consider. The company's valuation metrics are also weak. Overall, the company exhibits good long-term financial health but needs to address its short-term liquidity and operational efficiency.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
37.09
Industry Median
23.93
Small Cap Median
23.93
P/E RATIO
37.70
P/B RATIO
5.71
Industry Median
2.53
Small Cap Median
2.53
P/S RATIO
2.53
Industry Median
1.35
Small Cap Median
1.35
Others
PEG RATIO
0.86
EV/EBITDA RATIO
21.27
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹45.99 as on Jun 15, 2026.
Growth Score : 10.00The company shows strong growth. The revenue growth rate, operating profit growth rate, earnings per share growth, asset growth rate, and net income growth rate are all high, indicating robust expansion and improved profitability. This suggests the company is effectively capturing market opportunities and enhancing shareholder value.
Revenue Growth RateExcellentOperating Profit Growth RateExcellentEarnings Per Share (EPS) GrowthExcellentAsset Growth RateExcellentNet Income Growth RateExcellent| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | -0.82 | 15.7 | 3.57 | 4.14 | 36.42 |
| Operating Profit Growth Rate | 40 | 42.86 | 30 | 15.38 | 13.33 |
| Earnings Per Share (EPS) Growth | 87.1 | 50 | 14.94 | 22 | 29.51 |
| Asset Growth Rate | 1.32 | 12.99 | 10.34 | 25 | 27.5 |
| Net Income Growth Rate | 66.67 | 40 | 14.29 | 25 | 30 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Kilitch Drugs (India) Ltd | 7.12 | 22.83 | Neutral | 37.00 | 9.27 | 30.00 |
| 2 | Medico Remedies Ltd | 6.61 | 37.70 | Overvalued | 17.00 | 1.58 | 13.00 |
| 3 | Kopran Ltd | 6.60 | 40.82 | Undervalued | 62.00 | 6.30 | 26.00 |
| 4 | SMS Lifesciences India Ltd | 6.59 | 22.25 | Undervalued | 45.00 | 58.80 | 19.00 |
| 5 | Infinium Pharmachem Ltd | 6.42 | 33.97 | Neutral | 22.00 | 6.43 | 14.00 |
| 6 | Medicamen Biotech Ltd | 5.73 | 37.61 | Neutral | 20.00 | 6.94 | 10.00 |
| 7 | Aarey Drugs & Pharmaceuticals Ltd | 5.73 | 60.35 | Neutral | 7.00 | 1.40 | 4.00 |
| 8 | Albert David Ltd | 5.63 | -333.98 | Neutral | 5.00 | -2.62 | -1.00 |
| 9 | BPL Ltd | 5.46 | -28.58 | Neutral | -4.82 | -1.69 | -8.55 |
| 10 | Zim Laboratories Ltd | 5.41 | 108.20 | Neutral | 30.00 | 1.11 | 6.00 |
| 11 | Lyka Labs Ltd | 4.77 | -26.63 | Neutral | -4.00 | -8.93 | -10.00 |
| 12 | Nectar Lifescience Ltd | 3.83 | -0.80 | Neutral | -59.00 | -2.95 | -293.00 |
| 13 | PANCHSHEEL | N/A | N/A | N/A | N/A | N/A | N/A |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Hour Timeframe
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
No Stock Reports Available at This Moment.
Medico Remedies Ltd is an Indian pharmaceutical company specializing in the manufacturing and marketing of diverse pharmaceutical formulations. Its product portfolio spans various therapeutic categories like anti-infectives, pain management, and cardiovascular drugs. The company serves both domestic and international markets, committed to delivering quality and affordable healthcare solutions.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Medico Remedies Ltd's P/E ratio (TTM) is 37.09, compared to the industry median of 23.93 and large cap median of 23.93.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Medico Remedies Ltd's P/B ratio is 5.71, compared to the industry median of 2.53 and large cap median of 2.53.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Medico Remedies Ltd's P/S ratio is 2.53, compared to the industry median of 1.35 and large cap median of 1.35.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Medico Remedies Ltd's PEG ratio is 0.86.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Medico Remedies Ltd's EV/EBITDA ratio is 21.27.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Medico Remedies Ltd's ROE is 17.11%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Medico Remedies Ltd's ROA is 11.11%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Medico Remedies Ltd's ROCE is 23%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Medico Remedies Ltd's operating margin is 8.25%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Medico Remedies Ltd's net margin is 6.31%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Medico Remedies Ltd's current ratio is 1.66.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Medico Remedies Ltd's debt-to-equity ratio is 0.01.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Medico Remedies Ltd's interest coverage ratio is 10.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Medico Remedies Ltd's DPS is ₹0.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Medico Remedies Ltd's EPS is 29.51.
(Source line: "Ratios as of 26 Sept 2026, based on last traded price of ₹45.99. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 1985
Headquarters: Mumbai, Maharashtra
Core Offerings: Tablets, Capsules, Liquid Orals, Injections, Ointments
Stock Listing: NSE (MEDICO), BSE (540937)
Promoter: Mehta Family
Incorporated in 1985 as Medico Remedies Pvt. Ltd. Converted to a Public Limited Company in 1992. Over decades, the company has focused on expanding its manufacturing capabilities and diversified its product portfolio across various therapeutic areas. Migrated to the main board of BSE from the SME platform in 2019. Currently serves both the Indian and international pharmaceutical markets.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Pharmaceutical Business | 100% | Not specifically segmented |
Pharmaceutical Formulations: Engaged in the manufacturing of a broad spectrum of finished dosage forms, including tablets, capsules, liquid orals, injections, and ointments.
Therapeutic Areas: Products cater to diverse therapeutic segments such as anti-infectives, anti-inflammatory, pain management, cardiovascular, anti-diabetics, and vitamins.
Market Presence: Serves the domestic Indian market through a robust distribution network and exports its products to various international markets.
Mr. Milind D. Mehta (Managing Director): A qualified Pharmacist with extensive experience in pharmaceutical manufacturing, marketing, and business development, leading the company since its inception.
No major subsidiaries reported.
Bonus issue (1:1) in August 2022. No other major recent corporate actions on record.
The Medico Remedies Ltd share price today is ₹45.99 on NSE (MEDICO), as of 26 Sept 2026.
As of 26 Sept 2026, Medico Remedies Ltd share price is ₹45.99, with previous close ₹45.99. Today's range is ₹45.99 to ₹45.99. The 52-week range is ₹N/A to ₹N/A.
As of today, Medico Remedies Ltd's market cap is ₹381.72 crore (Small Cap).
Medico Remedies Ltd's current P/E ratio is 37.09, compared to the PHARMACEUTICALS & BIOTECHNOLOGY sector average of 35.
Medico Remedies Ltd's current P/B ratio is 5.71.
Medico Remedies Ltd's current dividend yield is N/A. Last dividend of ₹1.00 per share was declared on 25-Aug-2023.
Medico Remedies Ltd's EPS (TTM) is ₹29.51.
Medico Remedies Ltd is an Indian pharmaceutical company specializing in the manufacturing and marketing of diverse pharmaceutical formulations. Its product portfolio spans various therapeutic categories like anti-infectives, pain management, and cardiovascular drugs. The company serves both domestic and international markets, committed to delivering quality and affordable healthcare solutions.
Medico Remedies Ltd is promoted by Mehta Family, holding 61.38% as of 26 Sept 2026.
Medico Remedies Ltd is listed on NSE (MEDICO) and BSE (540937). Its next quarterly results are expected on August 2024 (Q1 FY25).
